Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) fell 4.6% on Tuesday . The company traded as low as $4.15 and last traded at $4.16, with a volume of 109,115 shares trading hands. The stock had previously closed at $4.36.

A number of research firms have recently weighed in on TTPH. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 14th. Wedbush restated a “neutral” rating and set a $4.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Monday, June 20th. Gabelli restated a “neutral” rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 16th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Saturday, May 14th. Finally, BMO Capital Markets initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, April 11th. They set a “market perform” rating and a $8.00 price objective for the company. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $20.80.

The firm’s market cap is $150.45 million. The firm has a 50 day moving average of $4.19 and a 200 day moving average of $4.75.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by $0.02. The company had revenue of $2 million for the quarter, compared to the consensus estimate of $2.20 million. During the same period in the previous year, the business posted ($0.66) earnings per share. The company’s revenue for the quarter was down 33.3% compared to the same quarter last year. Equities analysts forecast that Tetraphase Pharmaceuticals Inc. will post ($1.96) EPS for the current year.

A hedge fund recently raised its stake in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System raised its stake in Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 at the end of the most recent quarter.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.